Journal Mobile Options
Table of Contents
Vol. 32, No. 3, 1991
Issue release date: 1991
Gynecol Obstet Invest 1991;32:129–133

Tissue Anticoagulants in the Human Placenta: Preliminary Study with a Heparin-Like Anticoagulant and Review of the Literature

Uszynski M.
Department of Propaedeutical Medicine, University School of Medicine, Bydgoszcz, Poland

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


In this study a new heparin-like anticoagulant in the human placenta is described and an extensive review of the literature is given. An anticoagulant with a heparin-like activity was isolated from an extract of the human placenta. A two-stage purification procedure was applied: affinity chromatography on heparin-Sepharose and ion-exchange chromatography on DEAE-trisacryl. The isolated anticoagulant fraction was found to prolong both thrombin clotting time and activated partial thromboplastin time and to increase the activity of antithrombin III and heparin cofactor II. The placental-tissue anticoagulants described in the literature are divided by the author into five groups: (1) acidic peptides of low molecular weight; (2) thrombomodulin; (3) phospholipid-binding protein anticoagulants; (4) heparin-like anticoagulants, and (5) others. The anticoagulant described in the present study has been classified to the 4th group.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50